As of 13 January, the likelihood of approval (LoA) for Allergan’s cenicriviroc (CVC) for NASH in the US fell 17 points, according to GlobalData’s LoA data. The score change was based on the Phase III AURORA trial registry page getting updated to note that the study has been terminated due to Part I results showing lacking efficacy.

While the LoA prior to this update was 20%, GlobalData’s analysis using a combination of machine learning and a proprietary algorithm has lowered the LoA to 3%. Allergan is now part of AbbVie, which announced the closing of the acquisition—valued at approximately $63bn—on 8 May 2020. AbbVie’s market cap is $183.11bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CVC trial results were underwhelming

In November 2018, this news service reported that CVC drew mixed expert sentiments for Phase III AURORA trial success. The Phase II CENTAUR results demonstrated an underwhelming inflammation impact, and the observed placebo effect made available data harder to interpret, interviewed experts noted.

In fact, the foggy Phase IIb data may have contributed to AURORA patient accrual delays, this news service subsequently reported 13 April 2019. Two sources familiar with the trial said at the time that AURORA was notably behind its enrolment target. AURORA enrolled its first patient on 20 April 2017 and aimed to recruit a total of 1,779 participants, according to ClinicalTrials.gov.